<DOC>
	<DOC>NCT00808288</DOC>
	<brief_summary>To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)</brief_summary>
	<brief_title>A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Postbronchodilator FEV1/FVC ratio &lt;0.7 and a postbronchodilator FEV1 of 5080%. Diagnosis of moderate COPD for a minimum of 6 months. Stable disease for at least 1 month prior to screening More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalisation for the treatment of COPD within 3 months of screening or more than twice during the preceding year. History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>COPD Respiratory Long acting beta agonist</keyword>
</DOC>